# Healionics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healionics

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.healionics.com
- Total disclosed funding: $5.5M
- Latest round: Series A (Feb 20, 2024)
- Investors on record: 6

## About

Established in 2007 by Andrew J Marshall (CTO), Buddy Ratner, Christopher Somogyi, Max Maginness (COO), and Michel Alvarez, and based in Washington, US, Healionics Corporation operates as a manufacturer of medical devices that help improve bloodstream access for dialysis in patients with kidney failure. In February 2024, Healionics Corporation raised USD 2.85 million in Series A funding led by Keiretsu Capital, with participation from other investors.

The firm’s primary product, the STARgraft, is a synthetic vascular graft designed to address issues of occlusion and infection in a wide variety of implantable device applications. The STARgraft utilizes Healionics' STAR® biomaterial, which aims to enhance biointegration and tissue regeneration while reducing scarring and infection. 

The company intends to use the February 2024 funding to finish an ongoing human trial, obtain regulatory approval, and bring its STARgraft vascular graft to market.

## Funding rounds

- Series A, Feb 20, 2024, $2.9M — Keiretsu Capital
- Series B, Dec 11, 2008, $2.6M — Keiretsu Forum, Alliance of Angels, Bellingham Angel Investors, ZINO Society, Tacoma Angel Network

## Investors

- Keiretsu Forum — Series B
- Alliance of Angels (https://capitalatlas.ai/funds/alliance-of-angels) — Series B
- Bellingham Angel Investors (https://capitalatlas.ai/funds/bellingham-angel-investors) — Series B
- ZINO Society — Series B
- Tacoma Angel Network — Series B
- Keiretsu Capital (https://capitalatlas.ai/funds/keiretsu-capital) — Series A